Form 8-K · Current report
Pfizer 8-K, filed Nov 3, 2026
- Filed
- CIK
- 0000078003
- Accession no.
- 0000078003-26-000132
Summary
Pfizer's board unanimously appointed Cecile Guegan as Chief Financial Officer and Executive Vice President, effective November 1, 2026, after she served as interim CFO since August 16, 2026. CEO Albert Bourla said Guegan's experience would provide financial discipline as the company pursues growth, and Guegan said her focus remains on disciplined capital allocation and targeted investments.
Key points
- Guegan's compensation includes an annual base salary of $1,300,000 and an annual target cash incentive opportunity of $1,300,000.
- Guegan joined Pfizer through its 2009 acquisition of Wyeth, where she was CFO supporting Asia Pacific and EMEA/Canada businesses.
- She was Senior Vice President of Finance for Pfizer's Global Biopharmaceuticals business since 2022 and previously VP of Finance for Research & Development and Business Office from 2020 to 2022.
- She holds a master's degree in Management (Audit and Finance) from the Graduate School of Management of Brest, France, and a bachelor's degree in Accounting.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
- 9.01Financial Statements and Exhibits
From the filing
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 3, 2026, Pfizer Inc. (the “Company”) announced that the Board of Directors of the Company unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026 (the “Effective Date”). As reported in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 18, 2026, Ms. Guegan, 55, was previously appointed as the Company’s Interim Chief Financial Officer, effective August 16, 2026. Ms. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.